Nefopam Hydrochloride Crescent Pharma

Nefopam Hydrochloride, the active ingredient in Nefopam Hydrochloride Crescent Pharma, is a non‑opioid centrally acting analgesic presented as an oral formulation for oral use. It is employed to manage moderate acute pain, post‑operative discomfort and musculoskeletal pain in adult patients. GNH USA supplies Nefopam Hydrochloride Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nefopam Hydrochloride is a centrally acting analgesic used for several pain‑related conditions. - Moderate acute pain: provides relief when pain is of moderate intensity and requires non‑opioid therapy. - Post‑operative pain: helps control pain after surgical procedures, facilitating recovery. - Musculoskeletal pain: reduces discomfort associated with muscle, joint or skeletal injuries.

Nefopam Hydrochloride may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Dry mouth: reduced salivation leading to a feeling of thirst. - Sweating: increased perspiration, especially in warm environments. - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness or unsteadiness. - Blurred vision: temporary visual disturbances. - Constipation: reduced bowel motility.

Serious or Rare Side Effects: - Tachycardia: rapid heart rate that may require medical attention. - Seizures: rare occurrence, particularly in patients with seizure history. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, or swelling of the face and throat. - Hepatotoxicity: abnormal liver function tests. - Hematologic abnormalities: rare cases of blood dyscrasias.

Before prescribing Nefopam Hydrochloride, clinicians should consider several safety aspects. - Cardiovascular disease: monitor heart rate and blood pressure in patients with known cardiac conditions. - Seizure disorders: avoid use or use with caution in individuals with a history of seizures. - Liver impairment: adjust therapy if hepatic function is compromised. - Renal impairment: consider dose adjustment in severe renal dysfunction. - Concomitant MAO inhibitors: discontinue MAO inhibitors at least 14 days before starting Nefopam. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Nefopam Hydrochloride can interact with several drug classes, affecting safety or efficacy.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Tricyclic antidepressants: additive anticholinergic effects and increased cardiovascular risk. - Antihypertensive agents: may potentiate hypotensive effects.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - Anticholinergic drugs: heightened dry mouth and constipation. - CYP450 substrates: Nefopam may inhibit certain enzymes, altering plasma levels of co‑administered drugs.